System C: Potential Acquirers

Why It Matters

The transaction offers a rare platform that bridges acute and community care, giving acquirers a data‑rich foundation for AI and integrated‑care services, while delivering a strong cash‑flow return for investors.

Key Takeaways

• EBITDA grew four‑fold to £46 m ($58 m) by 2026.
• Recurring revenue exceeds 90% with churn below 2%.
• Combines acute EPR and social‑care software under one platform.
• Valuation targets £750‑£900 m ($950‑$1.14 bn) enterprise value.

Pulse Analysis

The UK health‑tech market is entering a consolidation wave driven by the NHS’s move from frontline digitisation to integrated, AI‑enabled care. System C has capitalised on this shift, expanding EBITDA from £12 million in 2021 to an estimated £46 million ($58 million) in 2026 and lifting revenue to roughly £130 million ($165 million). Its cloud‑native CareFlow and LiquidLogic suites now serve 40 NHS hospitals and the majority of English local authorities, positioning the firm as a critical data conduit between acute hospitals and community‑based social services. This scale, combined with a 90%+ recurring revenue mix and sub‑2% churn, creates a cash‑flow profile that is rare in the public‑sector software space.

Strategic buyers see System C as a gateway to AI‑driven clinical intelligence and a unified care platform. The company’s extensive longitudinal datasets—spanning oncology, maternity, and medicines management—feed ambient AI assistants that can automate documentation and support outcome‑based procurement, aligning with the NHS’s 10‑Year Plan and emerging value‑based contracts. For software groups like The Access Group or Civica, the acquisition would fuse acute‑care EPRs with social‑care back‑office tools, unlocking cross‑sell opportunities across HR, payroll, and finance modules. US hyperscalers such as Oracle or Microsoft could leverage the platform to deepen their cloud services in a market where competitors like Epic face high implementation costs and closed ecosystems.

Valuation expectations of £750‑£900 million ($950‑$1.14 billion) reflect a premium multiple justified by the platform’s high margins—approaching 40% EBITDA—and its strategic fit in a market where data compliance (EHDS, EU AI Act) adds scarcity value. Potential acquirers range from domestic champions seeking a national champion status to private‑equity funds hunting a roll‑up platform for further European expansion. The sale is poised to be one of the largest UK health‑tech exits of 2026, setting a benchmark for future deals and underscoring the strategic importance of integrated, data‑rich health‑software ecosystems.